20,300 Shares in Indivior PLC $INDV Purchased by LSV Asset Management

LSV Asset Management bought a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 20,300 shares of the company’s stock, valued at approximately $489,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its stake in shares of Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after acquiring an additional 1,299,425 shares during the period. Jane Street Group LLC lifted its position in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after purchasing an additional 958,132 shares during the period. State of New Jersey Common Pension Fund D bought a new position in Indivior during the 2nd quarter valued at $262,000. Y Intercept Hong Kong Ltd increased its position in shares of Indivior by 17.4% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock valued at $375,000 after purchasing an additional 3,769 shares during the period. Finally, Amalgamated Bank bought a new stake in shares of Indivior in the 2nd quarter worth $61,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Trading Up 0.5%

NASDAQ INDV opened at $34.75 on Wednesday. Indivior PLC has a 1 year low of $7.62 and a 1 year high of $38.00. The company has a market cap of $4.34 billion, a PE ratio of 37.77 and a beta of 0.80. The stock’s 50-day moving average price is $34.86 and its two-hundred day moving average price is $29.45.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on INDV. HC Wainwright raised their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price target on shares of Indivior in a report on Tuesday, January 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Finally, Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Insider Buying and Selling at Indivior

In other Indivior news, Director Daniel A. Ninivaggi purchased 775 shares of the stock in a transaction dated Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director owned 16,923 shares of the company’s stock, valued at $598,904.97. This represents a 4.80% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David E. Wheadon purchased 1,771 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the transaction, the director directly owned 14,395 shares of the company’s stock, valued at $509,439.05. This trade represents a 14.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 4,871 shares of company stock valued at $172,385 over the last three months.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.